{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:52:21Z","timestamp":1772023941331,"version":"3.50.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In 2020, for the great majority of patients with chronic phase chronic myeloid leukemia (CML), life expectancy is unaffected by a diagnosis of CML because of the unparalleled efficacy of ABL-targeted tyrosine kinase inhibitors (TKIs) in halting disease progression. A wealth of choices exist for first-line treatment selection, including the first-generation TKI imatinib and the second-generation TKIs bosutinib, dasatinib, and nilotinib. How I select first-line therapy between first-generation and second-generation TKIs is discussed in the context of patient-specific CML disease risk, therapy-related risks, and treatment goals. Although rare, identifying patients with CML at higher risk for disease progression or resistance is important and influences first-line TKI selection. I review the impact of first-generation vs second-generation TKI selection on treatment response and outcomes; the ability to achieve, as well as the timing of, treatment-free remission; and the impact of specific TKIs on longer-term health.<\/jats:p>","DOI":"10.1182\/hematology.2020000108","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:06:35Z","timestamp":1607137595000},"page":"228-236","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?"],"prefix":"10.1182","volume":"2020","author":[{"given":"Vivian G.","family":"Oehler","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2020121621163587100_B1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2020121621163587100_B2","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020121621163587100_B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2020121621163587100_B4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41375-018-0136-7","article-title":"Validation of the EUTOS long-term survival score in a recent independent cohort of \u201creal world\u201d CML patients","volume":"32","author":"Geelen","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"2020121621163587100_B5","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"issue":"26","key":"2020121621163587100_B6","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2020121621163587100_B7","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann Hematol"},{"issue":"22","key":"2020121621163587100_B8","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020121621163587100_B9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"key":"2020121621163587100_B10","author":"National Comprehensive Cancer Network (NCCN)"},{"issue":"4","key":"2020121621163587100_B11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"2020121621163587100_B12","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2020121621163587100_B13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020121621163587100_B14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2020121621163587100_B15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020121621163587100_B16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"issue":"20","key":"2020121621163587100_B17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020121621163587100_B18","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2020121621163587100_B19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020121621163587100_B20","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2020121621163587100_B21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and &gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020121621163587100_B22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"2020121621163587100_B23","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2020121621163587100_B24","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2352-3026(16)30167-3","article-title":"Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial","volume":"3","author":"Cortes","year":"2016","journal-title":"Lancet Haematol"},{"issue":"6","key":"2020121621163587100_B25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2020121621163587100_B26","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1002\/cam4.2545","article-title":"Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States","volume":"8","author":"Abou Dalle","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"2020121621163587100_B27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2020121621163587100_B28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/bloodadvances.2018028035","article-title":"The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia","volume":"3","author":"Minson","year":"2019","journal-title":"Blood Adv"},{"key":"2020121621163587100_B29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","article-title":"Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors","volume":"301","author":"Caocci","year":"2020","journal-title":"Int J Cardiol"},{"issue":"suppl 1","key":"2020121621163587100_B30","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2019-128761","article-title":"Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: ENESTnd 10-year analysis [abstract]","volume":"134","author":"Hughes","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2020121621163587100_B31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2020121621163587100_B32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2020121621163587100_B33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"key":"2020121621163587100_B34","doi-asserted-by":"crossref","first-page":"2045894019865704","DOI":"10.1177\/2045894019865704","article-title":"EXPRESS: pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors","volume":"9","author":"El-Dabh","year":"2019","journal-title":"Pulm Circ"},{"issue":"1","key":"2020121621163587100_B35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"2020121621163587100_B36","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"7","key":"2020121621163587100_B37","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"2020121621163587100_B38","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/bloodadvances.2019000195","article-title":"Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib","volume":"3","author":"Kok","year":"2019","journal-title":"Blood Adv"},{"key":"2020121621163587100_B39","article-title":"The out-of-pocket cost burden for specialty drugs in Medicare part D in 2019","volume-title":"Kaiser Family Foundation issue brief","author":"Cubanski","year":"1, 2019"},{"issue":"21","key":"2020121621163587100_B40","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv"},{"issue":"15 suppl","key":"2020121621163587100_B41","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2018.36.15_suppl.7002","article-title":"Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-mo follow-up [abstract]","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/228\/1794869\/hem2020000108c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/228\/1794869\/hem2020000108c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:12:36Z","timestamp":1608315156000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/228\/474324\/Firstgeneration-vs-secondgeneration-tyrosine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000108","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}